Studies have shown that active fund managers routinely underperform the S&P500 index*​

The Oncology Institute, Inc. (NASDAQ: TOI)

TOI Stock Predictions and Ratings

WSX Rating:
BUY
WSX Forecast (1yr):
18.90%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
-21.20%

TOI Stock Analysis

TOI PE Ratio:

TOI PEG Ratio: Not Available

TOI Forward EPS Growth (12 month): 0.00%

TOI PS Ratio: 0.8

TOI PSG Ratio:

TOI Forward Revenue Growth (12 month): 24.80%

TOI Articles

No data was found